The Supreme Court today (May 13) dismissed the plea filed by the Competition Commission of India (CCI) challenging a glass ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

The Indian stock markets ended lower on Tuesday as investors booked profits following Monday’s sharp rally. The sell-off was ...

Donald Trump’s new drug pricing order has the Indian pharmaceutical industry on edge. While CDMOs may benefit, generics and ...

The Indian Pharmaceutical Alliance (IPA) emphasizes the need to balance innovation with affordability in response to ...

The key equity indices traded with major losses in early afternoon trade, weighed down by profit booking and weakness in ...

The generic medicine industry of India is unlikely to be impacted by United States president Donald Trump's decision to slash drug prices in the US drastically, said Sudarshan Jain, Secretary General ...

While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account ...

Equity benchmarks tumble as IT stocks lead decline despite easing geopolitical tensions, with markets opening lower.

The BSE Sensex witnessed sharp profit-booking in Tuesday’s session, dragged down by heavyweight IT stocks. The index declined ...

The BSE Sensex tumbled 1,281.68 points, or 1.5%, to close at 81,148.22 levels, and the NSE Nifty50 settled at 24,578.35, down ...